Zandelisib is a selective dual PI3K/mTOR inhibitor that functions as a potent kinase inhibitor for the treatment of various solid tumors, particularly those associated with specific PI3K pathway mutations… Read more
Zandelisib is a selective dual PI3K/mTOR inhibitor that functions as a potent kinase inhibitor for the treatment of various solid tumors, particularly those associated with specific PI3K pathway mutations like breast cancer and endometrial carcinoma. Analytical laboratories utilize this category to support rigorous quality control and method validation processes for drug development. The collection includes the parent drug alongside high-quality stable isotope labelled compounds such as Zandelisib-13c-d3, which are essential tools for mass spectrometry-based assays. These reference standards provide the necessary precision for accurate impurity profiling, pharmacokinetic studies, and the metabolic monitoring of the active pharmaceutical ingredient. By offering these well-characterized materials, laboratories can ensure the sensitivity and reliability of their analytical protocols when assessing the safety and efficacy of therapeutic formulations during clinical and pre-clinical evaluations.